October 2012

National Institute of Malaria Research (NIMR) was established in 1977 as 'Malaria Research Centre', which was renamed as 'National Institute of Malaria Research' in November 2005. NIMR is one of the institutes of the Indian Council of Medical Research (an autonomous body under Department of Health Research, Ministry of Health & Family Welfare, Govt. of India).

About Authors:
Segu Sairam*, Mulla Mahaboob Basha, S Ananda Thangadurai, V Kranthi kumar
Swamy vivekanandha college of pharmacy, dept. Of pharmaceutical analysis,
Elayampalayam, tiruchengode – 637205.
*Sairampharma2020@gmail.com

ABSTRACT
A simple, sensitive and specific method reverse phase - high performance liquid chromatography (RP-HPLC) have been developed and validated for the estimation of Temozolomide in its Pharmaceutical dosage form.
Estimation of Temozolomide by using RP-HPLC coupled with UV
An isocraticREVERSE PHASE - HIGH PERFORMANCE LIQUID CHROMATOGRAPHY method was developed and validated for the estimation of Temozolomide in its Pharmaceutical dosage forms. The separation of the analytes was performed on aDevelosil ODS MG.5 (150×4.6mm),5µm, with mobile phase containing (0.5% w/v glacial acetic acid) named as Solution-A  :  Methanol  [90 : 10, v / v] was used. The flow rate was 1 ml min^-1 and separation was monitored by UV detection at 254 nm. Chromatogram showed peak at a retention time of 7.306 ± 0.009 min. validation of the method for linearity and range, intra-day and inter-day precision, accuracy, specificity, recovery, ruggedness, robustness and limits of detection and quantification were obtained as 0.598 µg / ml and 1.81 µg / ml respectively. The calibration plot was linear from 20-60 µg ml^-1 and the correlation coefficient was 0.999.The proposed method is fast, accurate and precise for the quantitative determination of Temozolomide capsules.

About Author:
Himani Sharma
B.Pharm, RGTU
shimani53@gmail.com

ABSTRACT
Nanotechnology provide innovative tools that shed greater light on life cycle of normal cells and the point at which molecular processes and changes within cells become correlated with development of cancer. It should be possible to obtain large amount of information from a small source. They aid in analysis of parameters such as cellular mechanics, morphology and cytoskeleton which has been hard to achieve using conventional technology. Nano devices can detect cancer cells, identify cancer signatures and provide targeted delivery of anti cancer therapeutics and contrast agents to tumour cells. Nanotechnology is potential tool that could help detect the molecular changes and assist in focusing on preventive efforts. Nanotechnologies for medical applications have been maturing. Several therapeutic formulations entered clinical trials and are expected to have an impact on how cancer treatment is done in the future.

About Authors:
Satyanand Tyagi*
*President, Tyagi Pharmacy Association & Scientific Writer,
Chattarpur, New Delhi, India-110074.
Prof. Satyanand Tyagi is a life time member of various pharmacy professional bodies like IPA, APTI and IPGA. He has published various research papers and review articles. His academic works include 49 Publications (41 Review Articles and 08 Research Articles of Pharmaceutical, Medicinal and Clinical Importance, published in standard and reputed National and International Pharmacy journals; Out of 49 publications, 11 are International Publications).
*sntyagi9@yahoo.com, +91-9871111375 / 9582025220

ABSTRACT:
Erlotinib is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). It is marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche. In lung cancer, it extends life by an average of 3.3 months at a cost of CDN $ 95,000. The hydrochloride salt of a quinazoline derivative of the drug shows antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. Erlotinib hydrochloride is approved to be used alone or with other drugs to treat:
* Non-small cell lung cancer that is locally advanced or has metastasized (spread to other parts of the body). It is used in patients who have already been treated with other chemotherapy.
* Pancreatic cancer. It is used with gemcitabine hydrochloride in patients whose disease cannot be removed by surgery or has metastasized.

Erlotinib hydrochloride is also being studied in the treatment of other types of cancer. The aim of present article is to provide in depth knowledge about the drug Erlotinib as well as its role in treatment of non-small cell lung cancer as well as pancreatic cancer.The review has also focused about chemistry, pharmacology as well as clinical trial studies of the Erlotinib.